Opthea (ASX:OPT) EBITDA Margin %: -574,150.00% (As of Jun. 2025)


What is Opthea EBITDA Margin %?

Opthea ASX:OPT -7.14% EBITDA Margin % is -574,150.00% as of Jun. 2025. The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, Opthea ranks worse than 99.47% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Opthea's EBITDA for the six months ended in Jun. 2025 was A$-11.48 Mil. Opthea's Revenue for the six months ended in Jun. 2025 was A$0.00 Mil. Therefore, Opthea's EBITDA margin for the quarter that ended in Jun. 2025 was -574,150.00%.

Opthea  (ASX:OPT) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Opthea EBITDA Margin % Related Terms

Opthea EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Opthea's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Opthea EBITDA Margin % Chart

Opthea Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -72,924.44 -109,248.84 -124,830.43 -159,642.55 -497,947.37

Opthea Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -106,400.00 -157,976.92 -161,843.75 -480,821.05 -574,150.00

ASX:OPT vs REVB, ITRMF, ENSC: EBITDA Margin % Comparison

For the Biotechnology subindustry, Opthea's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opthea EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opthea's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Opthea's EBITDA Margin % falls into.


Opthea EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Opthea's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-189.22/0.038
=-497,947.37 %

Opthea's EBITDA Margin % for the quarter that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-11.483/0.002
=-574,150.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -574,150.00% mean?
Opthea (ASX:OPT) has a EBITDA Margin % of -574,150.00% as of Jun. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Opthea and its competitors. According to the industry distribution chart, Opthea ranks #940 out of 945 companies in the Biotechnology industry, placing it in the top 99.5%.
Is Opthea's EBITDA Margin % too high?
Opthea's current EBITDA Margin % is -574,150.00%. Based on the distribution chart, Opthea ranks #940 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Opthea's EBITDA Margin % compare to REVB and ITRMF?
According to the Biotechnology industry distribution chart, Opthea ranks #940 out of 945 companies for EBITDA Margin %. This places Opthea in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Opthea and its competitors. Opthea's current EBITDA Margin % is -574,150.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opthea stock overvalued right now?
Opthea (ASX:OPT) has a current EBITDA Margin % of -574,150.00%. The current EBITDA Margin % is -574,150.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Opthea (ASX:OPT), the current EBITDA Margin % is -574,150.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Opthea Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.